Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.
Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.